Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone in its mission to improve life and health through innovation and quality [1][8]. Company Overview - Established in December 2015 and headquartered in Shenzhen, North Chip Life is a national high-tech enterprise focused on the research, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [7][15]. - The company has been recognized as a national high-tech enterprise in 2018 and as a national-level specialized and innovative "little giant" enterprise in 2023 [7][15]. - North Chip Life has developed a complete chain for the independent research, production, and commercialization of high-end active interventional devices and consumables, achieving breakthroughs in domestic production processes and establishing an international quality system [7][15]. Market Performance - The IPO was sponsored by China International Capital Corporation, with an initial offering price of 17.52 yuan, which saw a 193% increase at opening and later surged by 396.58% to reach 87 yuan [3][10]. - As of the latest report, the stock price was 49.58 yuan, reflecting a 182.99% increase, with a total market capitalization of 20.7 billion yuan [3][10]. Industry Focus - North Chip Life specializes in the field of precise interventional diagnosis and treatment of cardiovascular diseases, which is characterized by a broad patient base, continuous clinical demand, and active technological innovation [5][13]. - The next decade is seen as a historic opportunity for the global medical device industry to accelerate towards intelligent and precise iterations, aligning with North Chip Life's vision of becoming a world-class medical technology enterprise with lasting influence [5][13]. Product Development - The company has obtained over 20 domestic and international Class III medical device registration certificates and has launched more than ten products, with several dozen more in development [7][15]. - Notable commercialized products include the first domestically innovative 60MHz high-definition intravascular ultrasound (IVUS) system and the first domestic flow reserve fraction (FFR) system approved by the NMPA [7][15]. - The company's pulse field ablation (PFA) system is the first PFA product in China to be included in the European Heart Rhythm Association's breakthrough clinical research progress, with clinical results published in the top cardiovascular journal JACC [8][16]. Global Reach - North Chip Life's core products are used in hospitals across 30 provinces in China and have been clinically applied in over 1,000 hospitals in more than ten countries, including Belgium, Germany, and Italy [8][16].
科创板迎新！北芯生命成第五套标准重启后首家上市医疗器械企业